Cardiovascular disease (CVD) and health care utilization (HCU) in patients (pts) with HR+, HER2 negative (HER2-) advanced breast cancer (ABC) on endocrine therapy with or without CDK4/6 inhibitor (CDK4/6i): A retrospective cohort study

被引：0
|
作者：
Dent, S. [1 ]
Alder, L. [1 ]
Broadwater, G. [1 ]
Hyslop, T. [1 ]
Oeffinger, K. [1 ]
Khouri, M. [1 ]
Balu, S. [2 ]
Kimmick, G. [1 ]
机构：
[1] Duke Canc Inst, Cardiooncol, Durham, NC USA
[2] Novartis Pharmaceut, HEOR, E Hanover, NJ USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
324P
引用
收藏
页码：S505 / S506
页数：2
相关论文
共 50 条
  • [31] Dalpiciclib. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, Treatment of HR+/HER2-and HER2+advanced breast cancer
    Wang, Jingru
    Dong, Xiaotong
    Ashby, Charles R.
    Chen, Zhe-Sheng
    Zhang, Yunxiang
    DRUGS OF THE FUTURE, 2022, 47 (12) : 867 - 886
  • [32] First-line CDK4/6 inhibitor treatment for HR+, HER2-negative metastatic breast cancer (MBC)
    Hoskins, Kent F.
    Richards, Paul
    Wisinski, Kari
    CANCER RESEARCH, 2018, 78 (13)
  • [33] Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2-metastatic breast cancer
    Zagami, Paola
    Esposito, Angela
    Salimbeni, Beatrice Taurelli
    Giachetti, Pier Paolo Maria Berton
    Scafetta, Roberta
    Lambertini, Matteo
    Di Maio, Massimo
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Cinieri, Saverio
    BREAST, 2025, 79
  • [34] Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer
    Sammons, Sarah
    Shastry, Mythili
    Dent, Susan
    Anders, Carey
    Hamilton, Erika
    CLINICAL BREAST CANCER, 2020, 20 (01) : 1 - 11
  • [35] Biomarkers of response to CDK4/6 inhibitor (CDK4/6i) in hormone receptor (HR) positive and HER2-positive breast cancer (BC) patient-derived xenografts (PDX)
    Palafox, Marta
    Herrera-Abreu, Maria Teresa
    Bellet, Meritxell
    Oliveira, Mafalda
    Bruna, Alejandra
    Rodriguez, Olga
    Guzman, Marta
    Grueso, Judit
    Vilaplana, Cristina
    Arribas, Joaquin
    di Tomaso, Emmanuelle
    Su, Faye
    Caldas, Carlos
    Turner, Nicholas C.
    Dienstmann, Rodrigo
    Baselga, Jose
    Scaltriti, Maurizio
    Cortes, Javier
    Saura, Cristina
    Serra, Violeta
    CANCER RESEARCH, 2018, 78 (13)
  • [36] Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2- Metastatic Breast Cancer: A Podcast
    Dong, Brian
    Lusen, Rita
    Chick, Ella
    Kline, Lisa
    ONCOLOGY AND THERAPY, 2023, 11 (04) : 411 - 418
  • [37] CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): A retrospective analysis of real-world data
    Martinez-Saez, O.
    Tolosa, P.
    Sanchez De Torre, A.
    Pascual, T.
    Braso-Maristany, F.
    Rodriguez Hernandez, A.
    Parrilla, L.
    Roncero, A. M.
    Ruano, Y.
    Chic, N.
    Schettini, F.
    Laguna, J. C.
    Sanfeliu Torres, E.
    Gonzalez-Farre, B.
    Vidal, M.
    Adamo, B.
    Guillen Sacoto, M. C.
    Munoz, M.
    Prat, A.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S30 - S30
  • [38] HR+/HER2-metastatic Breast Cancer Increasing Data Density of CDK4/6 Inhibitors
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (09) : 485 - 485
  • [39] Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer
    Jian Zhang
    Xiaojia Wang
    Xian Wang
    Aimin Hui
    Zhuli Wu
    Ling Tian
    Changjiang Xu
    Yuchen Yang
    Wenjing Zhang
    Xichun Hu
    Investigational New Drugs, 2021, 39 : 1549 - 1558
  • [40] Health care resource utilization and costs of Medicare-enrolled patients with HR+/HER2- metastatic breast cancer treated with a CDK4/6i in the first-line setting (vol 31, pg 6, 2025)
    Behan, E.
    Veenstra, D. L.
    Bansal, A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2025, 31 (02) : 226 - 226
12345